Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis
- DOI
- 10.1002/hon.70120
- Published
- 2025-07
- Container
- Hematological Oncology
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1002/hon.70120,
title = {Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis},
author = {Michèle Hoffmann and Barbara Jeker and Uyen Huynh‐Do and Yara Banz and Jeanne Godau and Elisabeth Weber and Ulrike Bacher and Thomas Pabst},
year = {2025},
journal = {Hematological Oncology},
doi = {10.1002/hon.70120},
url = {https://doi.org/10.1002/hon.70120}
}RIS
TY - JOUR TI - Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis AU - Michèle Hoffmann AU - Barbara Jeker AU - Uyen Huynh‐Do AU - Yara Banz AU - Jeanne Godau AU - Elisabeth Weber AU - Ulrike Bacher AU - Thomas Pabst PY - 2025 JO - Hematological Oncology DO - 10.1002/hon.70120 UR - https://doi.org/10.1002/hon.70120 ER -
APA
Hoffmann, M., Jeker, B., Huynh‐Do, U., Banz, Y., Godau, J., Weber, E., Bacher, U., & Pabst, T. (2025). Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis. Hematological Oncology. https://doi.org/10.1002/hon.70120
Source records
- crossref · retrieved 2026-09-25T11:16:35.908Z